A Phase 3 interventional study of Nivolumab and Carboplatin in Carcinoma, Non-Small-Cell Lung, sponsored by Bristol-Myers Squibb. Active, not recruiting at 108 sites in 22 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-26.
Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 120 studies testing nivolumab in Carcinoma, Non-Small-Cell Lung — 22 open to participants now, 44 under way, 6 of them phase 3. Nivolumab · Carcinoma, Non-Small-Cell Lung.
Among the 120 studies testing nivolumab in Carcinoma, Non-Small-Cell Lung, this one is the 16th largest by enrollment, is one of 9 that started in 2019, is one of 24 in phase 3, reaches primary completion later than 1 of the 43 other live ones, and was the 77th registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →22 of the 120 studies testing nivolumab in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:
University of Chicago · Sites in United States
Ages 18+
Washington University School of Medicine · Sites in United States
Ages 18+
Liza Villaruz, MD · Sites in United States
Ages 18+
Diwakar Davar · Sites in United States
Ages 18+
EuroCityClinic LLC · Sites in Russia
Ages 18+
By country, each count listing its studies:
Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, nivolumab is the treatment under test here. Read study by study →
120 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 27 · Phase 2 78 · Phase 3 24 · Phase 4 2
First in 2006; this study’s year is marked. 9 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 461 is above the median of 62 across 6,023 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 66 across the 120 interventional studies. Of the 62 that completed or were terminated, 44 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
36 of 120 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
131 studies in Carcinoma, Non-Small-Cell Lung by Bristol-Myers Squibb: 21 open now, 35 under way, 10 of them phase 3. Of 91 finished, 47 (52%) have results posted.
Among the 131 studies in Carcinoma, Non-Small-Cell Lung by Bristol-Myers Squibb, this one is the 24th largest by enrollment of the 107 interventional ones that give a count, is one of 6 that started in 2019, is one of 27 in phase 3, reaches primary completion later than 0 of the 34 other live ones, and was the 73rd registered.
Bristol-Myers Squibb’s Carcinoma, Non-Small-Cell Lung studies by the year they started, since 2000.
13 of the studies testing nivolumab in Carcinoma, Non-Small-Cell Lung that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02595944Phase 3National Cancer Institute (NCI)Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial) | 2027-05-31 |
| NCT03527108Fox Chase Cancer CenterNivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic NSCLC | 2026-12 |
| NCT05597800Universita di VeronaNivolumab/Ipilimumab and Chemotherapy Combination in Advanced NSCLC Patients With HIV, HBV, HCV and Long Covid Syndrome | 2026-12-31 |
| NCT06946797Bristol-Myers SquibbA Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC) | 2027-02-05 |
| NCT06275360VA Office of Research and DevelopmentRepositioning Immunotherapy in VetArans With Lung Cancer | 2027-02-28 |
Add all 13 to your calendar (.ics) → With an account.
Among the 120 studies testing nivolumab in Carcinoma, Non-Small-Cell Lung, from their registry updates:
Among Bristol-Myers Squibb’s 131 in Carcinoma, Non-Small-Cell Lung:
This tab as a report to print or save as PDF → With an account.
The main purpose of the study is to examine if periadjuvant (neoadjuvant, then adjuvant) immunotherapy will prolong event free survival in participants with early stage non-small cell lung cancer.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: Nivolumab · Drug: Carboplatin · Drug: Cisplatin · Drug: Paclitaxel · Drug: Pemetrexed · Drug: Docetaxel
Drug: Carboplatin · Drug: Cisplatin · Drug: Paclitaxel · Drug: Pemetrexed · Drug: Placebo · Drug: Docetaxel
Specified dose on specified days
Also known as: Opdivo, BMS936558
Specified dose on specified days
Specified dose on specified days
Specified dose on specified days
Specified dose on specified days
Specified dose on specified days
Specified dose on specified days
Event-Free Survival (EFS) by BICR
The length of time from randomization to any of the following events: progression of disease or worsening of disease precluding surgery, if surgery is attempted but gross resection is abandoned due to unresectable tumor or worsening of disease, progression or recurrence of disease after surgery, progression or recurrence of disease without surgery, or death due to any cause. Progression/recurrence will be assessed by BICR per RECIST 1.1. Participants who do not undergo surgery for reason other than progression will be considered to have an event at RECIST 1.1 progression or death
Time frame: From randomization to disease progression, worsening, recurrence, or death due to any cause (up to approximately 44 months)
Overall Survival (OS)
OS is defined as the time between the date of randomization and the date of death due to any cause. OS will be censored on the last date a subject was known to be alive.
Time frame: From randomization and the date of death due to any cause.
Pathologic Complete Response (pCR) Rate
Pathologic complete response (pCR) rate is defined as the percentage of randomized participants with absence of residual viable tumor in lung and lymph nodes as evaluated by blinded independent pathology review (BIPR).
Time frame: From randomization up to approximately 44 months
Major Pathological Response (MPR) Rate
Major pathological response (MPR) rate is defined as the percentage of randomized participants with ≤10% residual viable tumor in lung and lymph nodes as evaluated by blinded independent pathology review (BIPR).
Time frame: From randomization up to approximately 44 months
The Number of Participants With Adverse Events (AEs)
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment.
Time frame: From first treatment to 30 days after last treatment of study therapy including definitive surgery and radiotherapy (up to approximately 28 months)
The Number of Participants With Serious Adverse Events (SAEs)
Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is an important medical event.
Time frame: From first treatment to 30 days after last treatment of study therapy including definitive surgery and radiotherapy (up to approximately 28 months)
The Number of Participants With Select Adverse Events (AEs)
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Select AEs include endocrinopathies, diarrhea/colitis, hepatitis, pneumonitis, interstitial nephritis, and rash. Multiple event terms that may describe each of these were grouped into endocrine, GI, hepatic, pulmonary, renal, and skin select AE categories, respectively. Hypersensitivity/infusion reactions were analyzed along with the select AE categories.
Time frame: From first treatment to 30 days after last treatment of study therapy including definitive surgery and radiotherapy (up to approximately 28 months)
| Milestone | Nivolumab + SOC Chemotherapy | Placebo + SOC Chemotherapy |
|---|---|---|
| Started | 229 | 232 |
| Completed | 228 | 230 |
| Not completed | 1 | 2 |
| Withdrew: Participant withdrew consent | 0 | 1 |
| Withdrew: Participant no longer met study criteria | 1 | 1 |
| Milestone | Nivolumab + SOC Chemotherapy | Placebo + SOC Chemotherapy |
|---|---|---|
| Started | 228 | 230 |
| Neoadjuvant treatment | 228 | 230 |
| Adjuvant treatment | 142 | 152 |
| Completed | 85 | 92 |
| Not completed | 143 | 138 |
| Withdrew: Ongoing treatment | 10 | 8 |
| Withdrew: Disease progression/recurrence | 36 | 72 |
| Withdrew: Study drug toxicity | 36 | 13 |
| Withdrew: Death | 2 | 0 |
| Withdrew: Adverse event unrelated to study drug | 21 | 14 |
| Withdrew: Participant request to discontinue study treatment | 16 | 8 |
| Withdrew: Participant withdrew consent | 1 | 3 |
| Withdrew: Participant no longer meets study criteria | 3 | 2 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Other reasons | 15 | 17 |
| Withdrew: Administrative reason by sponsor | 0 | 1 |
| Withdrew: Not reported | 2 | 0 |
The length of time from randomization to any of the following events: progression of disease or worsening of disease precluding surgery, if surgery is attempted but gross resection is abandoned due to unresectable tumor or worsening of disease, progression or recurrence of disease after surgery, progression or recurrence of disease without surgery, or death due to any cause. Progression/recurrence will be assessed by BICR per RECIST 1.1. Participants who do not undergo surgery for reason other than progression will be considered to have an event at RECIST 1.1 progression or death
| Months | Nivolumab + SOC Chemotherapy | Placebo + SOC Chemotherapy |
|---|---|---|
| Event-Free Survival (EFS) by BICR | NA (28.94 to —) | 18.43 (13.63 to 28.06) |
OS is defined as the time between the date of randomization and the date of death due to any cause. OS will be censored on the last date a subject was known to be alive.
Results for this outcome have not been posted.
Pathologic complete response (pCR) rate is defined as the percentage of randomized participants with absence of residual viable tumor in lung and lymph nodes as evaluated by blinded independent pathology review (BIPR).
| Percentage of Participants | Nivolumab + SOC Chemotherapy | Placebo + SOC Chemotherapy |
|---|---|---|
| Pathologic Complete Response (pCR) Rate | 25.3 (19.8 to 31.5) | 4.7 (2.4 to 8.3) |
Major pathological response (MPR) rate is defined as the percentage of randomized participants with ≤10% residual viable tumor in lung and lymph nodes as evaluated by blinded independent pathology review (BIPR).
| Percentage of participants | Nivolumab + SOC Chemotherapy | Placebo + SOC Chemotherapy |
|---|---|---|
| Major Pathological Response (MPR) Rate | 35.4 (29.2 to 41.9) | 12.1 (8.2 to 17.0) |
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment.
| Participants | Nivolumab + SOC Chemotherapy | Placebo + SOC Chemotherapy |
|---|---|---|
| The Number of Participants With Adverse Events (AEs) | 222 | 225 |
Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is an important medical event.
| Participants | Nivolumab + SOC Chemotherapy | Placebo + SOC Chemotherapy |
|---|---|---|
| The Number of Participants With Serious Adverse Events (SAEs) | 96 | 71 |
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Select AEs include endocrinopathies, diarrhea/colitis, hepatitis, pneumonitis, interstitial nephritis, and rash. Multiple event terms that may describe each of these were grouped into endocrine, GI, hepatic, pulmonary, renal, and skin select AE categories, respectively. Hypersensitivity/infusion reactions were analyzed along with the select AE categories.
| Participants | Nivolumab + SOC Chemotherapy | Placebo + SOC Chemotherapy |
|---|---|---|
| Gastrointestinal Event | 37 | 37 |
| Hepatic Event | 46 | 31 |
| Pulmonary Event | 17 | 8 |
| Renal Event | 34 | 18 |
| Skin Event | 71 | 53 |
| Hypersensitivity/Infusion Reaction Event | 15 | 14 |
| Endocrine Event | 42 | 13 |
Collected over All-cause mortality was assessed from randomization to primary completion (up to approximately 44 months). SAEs and Other AEs were assessed from first dose to 100 days following last dose (up to approximately 30 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Nivolumab + SOC Chemotherapy | 40/229 (17.5%) | 109/228 (47.8%) | 214/228 (93.9%) |
| Placebo + SOC Chemotherapy | 48/232 (20.7%) | 83/230 (36.1%) | 212/230 (92.2%) |
| Event | Nivolumab + SOC Chemotherapy | Placebo + SOC Chemotherapy |
|---|---|---|
| PneumoniaInfections and infestations | 9/228 | 10/230 |
| Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 3/228 | 6/230 |
| Acute kidney injuryRenal and urinary disorders | 5/228 | 1/230 |
| HaemoptysisRespiratory, thoracic and mediastinal disorders | 5/228 | 3/230 |
| PneumonitisRespiratory, thoracic and mediastinal disorders | 5/228 | 4/230 |
| ColitisGastrointestinal disorders | 4/228 | 0/230 |
| COVID-19Infections and infestations | 4/228 | 2/230 |
| SepsisInfections and infestations | 4/228 | 0/230 |
| AnaemiaBlood and lymphatic system disorders | 1/228 | 4/230 |
| Atrial fibrillationCardiac disorders | 1/228 | 4/230 |
| Event | Nivolumab + SOC Chemotherapy | Placebo + SOC Chemotherapy |
|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 93/228 | 73/230 |
| NauseaGastrointestinal disorders | 67/228 | 78/230 |
| ConstipationGastrointestinal disorders | 72/228 | 65/230 |
| FatigueGeneral disorders and administration site conditions | 67/228 | 58/230 |
| AlopeciaSkin and subcutaneous tissue disorders | 59/228 | 64/230 |
| CoughRespiratory, thoracic and mediastinal disorders | 51/228 | 48/230 |
| Decreased appetiteMetabolism and nutrition disorders | 45/228 | 46/230 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 45/228 | 42/230 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 39/228 | 36/230 |
| DiarrhoeaGastrointestinal disorders | 37/228 | 36/230 |
| Age, Categorical(Participants) | Nivolumab + SOC Chemotherapy | Placebo + SOC Chemotherapy | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 102 | 100 | 202 |
| >=65 years | 127 | 132 | 259 |
| Age, Continuous(Years) | Nivolumab + SOC Chemotherapy | Placebo + SOC Chemotherapy | Total |
|---|---|---|---|
| Mean | 64.2 ± 7.9 | 64.6 ± 8.4 | 64.4 ± 8.1 |
| Sex: Female, Male(Participants) | Nivolumab + SOC Chemotherapy | Placebo + SOC Chemotherapy | Total |
|---|---|---|---|
| Female | 62 | 72 | 134 |
| Male | 167 | 160 | 327 |
| Ethnicity (NIH/OMB)(Participants) | Nivolumab + SOC Chemotherapy | Placebo + SOC Chemotherapy | Total |
|---|---|---|---|
| Hispanic or Latino | 9 | 17 | 26 |
| Not Hispanic or Latino | 128 | 113 | 241 |
| Unknown or Not Reported | 92 | 102 | 194 |
| Race (NIH/OMB)(Participants) | Nivolumab + SOC Chemotherapy | Placebo + SOC Chemotherapy | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 66 | 50 | 116 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 4 | 4 | 8 |
| White | 155 | 175 | 330 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 4 | 3 | 7 |
Showing the first 100 of 108 sites across 22 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: See Plan Description
Access criteria: See Plan Description
Data sharing details ↗ · www.bms.com
Ran from Nov 2019 to primary completion in Jul 2023, 44 months.
Results were first posted in Jul 2024, 11 months after primary completion.
Of 315 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's 44 months is above that.
Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nivolumab
Carcinoma, Non-Small-Cell Lung →